A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer

StatusUnknown
PhaseNot specified
Started

Record status This record was last updated September 19, 2024 (before its estimated January 1, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  2. Primary completion date: Jan 1, 2024 to Jan 1, 2025v5
  3. Primary completion date: Jan 1, 2023 to Jan 1, 2024
    • Start date: Jan 1, 2021 to Jan 1, 2023
    • Study completion date: Jan 12, 2023 to Jan 12, 2025
    v4
  4. Primary completion date: Jan 1, 2022 to Jan 1, 2023
    • Study completion date: Jan 1, 2023 to Jan 12, 2023
    v3
  5. Re-verified, no change to tracked fieldsv2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.
Trial Details
NCT Number NCT04777175
Lead Sponsor Yongchang Zhang
Collaborators: Hunan Province Tumor Hospital
Conditions
(from sponsor)		 Non Small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 186 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov